ESC 365 - The future of LDL lowering Recent data from PCSK9 inhibitors and outlook for upcoming trials.

ESC Premium Access

The future of LDL lowering Recent data from PCSK9 inhibitors and outlook for upcoming trials.

Session: LDL-Cholesterol lowering at a turning point

Topic: Lipids

Speaker: Professor U. Landmesser (Berlin, DE)

Event: EuroPRevent Meeting 2016

Congress Presentation

About the speaker

Professor Ulf Landmesser

Charite University Hospital, Berlin (Germany)

41 presentations

2 followers

3 more presentations in this session

2016 update on LDL as a risk factor.

Speaker: Professor L. Tokgozoglu (Ankara, TR)

Status of CVD Health and cholesterol in Europe

Speaker: Doctor S. Sans Menendez (Barcelona, ES)

PCSK9 inhibition: The new player in the field.

Speaker: Professor D. Ural (Istanbul, TR)

Access the full session

LDL-Cholesterol lowering at a turning point

Speakers: Professor U. Landmesser, Professor L. Tokgozoglu, Doctor S. Sans Menendez, Professor D. Ural

About the event

EuroPRevent Meeting 2016

14 June - 15 June 2016

Sessions Presentations

Congress

ESC 365 is supported by